The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply

Affiliations

¹ CZ Health Insurance, Tilburg, Netherlands.
² Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
³ Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.

Comment

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani et al. Lancet Oncol. 2022 May.

. 2022 May;23(5):e203.

doi: 10.1016/S1470-2045(22)00210-8.

¹ CZ Health Insurance, Tilburg, Netherlands.
² Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands.
³ Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX, Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.

No abstract available

Conflict of interest statement

The authors' declaration of interests remain the same as those disclosed in the original Comment.

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, Timmers L, Ly Tran TH, de Boer JE, de Wit GF, Geurts BS, Gelderblom H, Verheul HMW, Blijlevens N, Wymenga ANM, Eskens FALM, Smit EF, Bloemendal HJ, Voest EE. Zeverijn LJ, et al. Lancet Oncol. 2022 Feb;23(2):198-201. doi: 10.1016/S1470-2045(21)00707-5. Lancet Oncol. 2022. PMID: 35114116 No abstract available.
The DRUG Access Protocol: access inequality and European harmonisation.
Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. Polak TB, et al. Lancet Oncol. 2022 May;23(5):e202. doi: 10.1016/S1470-2045(22)00098-5. Lancet Oncol. 2022. PMID: 35489346 No abstract available.